ACADIA Pharmaceuticals Inc.
ACAD | NASDAQ
$26.50
+$0.11 (+0.40%)
Sep 22, 2026, 1:31 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.07B | 957.8M | 726.44M | 517.24M | 484.15M | 441.76M |
Cost of Revenue | 89M | 81.84M | 45.73M | 10.17M | 19.14M | 20.55M |
Gross Profit | 982.51M | 875.96M | 680.71M | 507.07M | 465M | 421.21M |
Operating Income | 104.81M | 230.79M | -73.38M | -223.6M | -170.44M | -286.59M |
Interest Income | 31.72M | 25.46M | 17.23M | 6.61M | 591K | 6.61M |
Pretax Income | 138.9M | 258.08M | -51.04M | -213.44M | -167.52M | -280.97M |
Net Income | 391M | 226.45M | -61.29M | -215.98M | -167.87M | -281.58M |
Selling & General & Admin | 548.89M | 488.43M | 402.47M | 369.09M | 396.03M | 388.66M |
Research & Development | 328.8M | 303.25M | 351.62M | 361.58M | 239.42M | 319.13M |
Other Expenses | n/a | -146.52M | n/a | n/a | n/a | n/a |
Operating Expenses | 877.7M | 645.16M | 754.09M | 730.67M | 635.44M | 707.79M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | 9.4M | n/a | n/a | n/a |
Cost & Expenses | 966.69M | 727M | 799.82M | 740.83M | 654.58M | 728.34M |
Income Tax Expense | -252.1M | 31.62M | 10.25M | 2.53M | 351K | 611K |
Shares Outstanding (Basic) | 169.34M | 165.72M | 163.82M | 161.68M | 160.49M | 157.33M |
Shares Outstanding (Diluted) | 171.36M | 166.36M | 163.82M | 161.68M | 160.49M | 157.33M |
EPS (Basic) | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 | -1.79 |
EPS (Diluted) | 2.29 | 1.36 | -0.37 | -1.34 | -1.05 | -1.79 |
EBITDA | 150.66M | 100.16M | -45.48M | -211.42M | -164.18M | -283.65M |
EBIT | 138.9M | 84.28M | -51.04M | -213.44M | -167.52M | -286.59M |
Depreciation & Amortization | 11.76M | 15.88M | 5.55M | 2.03M | 3.34M | 2.93M |
Add to Watchlist
Select watchlists to add or remove ACAD